Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect resulting from enhanced tumor-infiltrating DCs and macrophage infiltrate switching from M2 to M1 consequently produce increased IL-12 and tumor necrosis factor (TNF) (76).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intratumor injections of TLR9 ligand CpG and anti-IL10R antibody are able to reinforce antitumor efficacy in C26 and B16 animal models.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“Although the main function of dendritic cells (DCs) * is probably to orchestrate a defense against pathogens, DCs are also well equipped to initiate antitumor responses (1).”
BackgroundA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“We tested different combinations of substances with the aim of relieving tumor-mediated inhibition and simultaneously mediating DC activation, including combinations of the TLR-9 ligand CpG 1668 (21) and an anti–IL-10R blocking antibody (15).”
MethodMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291 · cited 4×
“In contrast, TIDCs from X/myc hepatocarcinoma were representative of distinct subsets of mouse DCs (19).”
BackgroundResultInfluentialKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“Indeed, it was recently reported that immature DC injection would induce antigen-specific T cell unresponsiveness in man (22).”
BackgroundMayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022 · cited 1×
“On the other hand, TIDCs isolated from liver hepatocarcinoma were more diverse, including CD11b and CD11b DCs as well as cells expressing CD8 an/or B220, the latter marker being ascribed to mouse type I IFN-producing cells (19, 20).”
BackgroundSelf-citationZou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · cited 1×
“Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Self-citation
Cited by
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
“Inhibition of IL-10 with an anti-IL-10 receptor antibody combined with CpG-ODN activation was shown to reverse the tolerogenic state of tumor-infiltrating DCs and to augment their therapeutic efficacy in a mouse tumor model (269).”
BackgroundCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Self-citationCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
“For example, blocking IL-10-receptor signalling, which probably involves inhibition of STAT3 activity, can markedly enhance CpG-oligodeoxynucleotide-induced anti-tumour immunit”
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Self-citationIPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,625
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Biology and therapeutic potential of interleukin-10
Saraiva, M., Vieira, P., & O’Garra, A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190418 · Cited by 1,118
Self-citationInterleukin‐10: new perspectives on an old cytokine
Mosser, D. M., & Zhang, X. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00706.x · Cited by 1,077
“In small animal models, these approaches are beginning to bear fruit (98).”
BackgroundIL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Self-citationInhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
“Blocking IL-10R has not been used extensively as an approach for anticancer therapy but has been reported to induce tumor regression in combination with CpG oligonucleotides in various subcutaneous tumor models, ostensibly through macrophage/DC activation and increased expression of IL-12 (Guiducci et al., 2005; Vicar…”
BackgroundInfluentialDendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
“One of the first examples of this involved treating tumor-bearing animals with CpG and an anti-IL-10 receptor antibody [89], with potentially comparable results obtained when using cytotoxic therapy as a surrogate immune agonist [28].”
ResultMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Self-citationMunn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
“Similarly, because IL-10 interferes with DC maturation (40), MDSC secreting high levels of IL-10 may indirectly block DC function.”
BackgroundGuiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
“In comparison with our previous work with CpG and anti–IL-10R alone (10), the addition of CCL16 allowed us to successfully treat tumors at least twice in size than those previously tested using a single rather than three injections.”
BackgroundResultInfluentialSelf-citationResolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
“For example, treatment with a combination of anti–IL-10R monoclonal antibody and Toll-like receptor 9 (TLR9) ligands had potent therapeutic antitumor eff ects (3, 4), indicating a role for IL-10 in the pathogenesis of cancer.”
BackgroundType I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 500
“However, as is the case 10 Trends in Immunology, Month Year, Vol. xx, No. yy with IFN-Is, IL-10 appears to have pleiotropic effects and, in some cases, may impede antitumor responses, while, in others, it may promote tumor clearance by driving CD8 T cell differentiation, IFN-g production, and APCmaturation [128,129].”
Dendritic Cells and Their Role in Immunotherapy
Gardner, A., de Mingo Pulido, Á., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Strategies for use of IL‐10 or its antagonists in human disease
O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., & Hawrylowicz, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00635.x · Cited by 452
“immune response in certain animal models of cancer (231)”
BackgroundSelf-citationTumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Tran Janco, J. M., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403134 · Cited by 440
“(73) showed that TIDCs (most of which were of the immature phenotype) that were refractive to stimulation by a combination of LPS, anti-CD40, and IFN-g could be rescued by treatment with a combination of CpG and anti–IL-10R Ab both in vitro and in vivo, leading to better de novo IL-12 production and antitumor immune r…”
BackgroundConejo-Garcia, J. R., Benencia, F., Courreges, M.-C., Kang, E., Mohamed-Hadley, A., Buckanovich, R. J., Holtz, D. O., Jenkins, A., Na, H., Zhang, L., et al. (2004) · Nature Medicine · doi:10.1038/nm1097 · Cited by 437
Development of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells
Levings, M. K., Bacchetta, R., Schulz, U., & Roncarolo, M. G. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000067596 · Cited by 422
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
“, 2001) but derail immunization and inhibit memory responses to tumor antigens (Fujii et al., 2001; Vicari et al., 2002).”
BackgroundOX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Self-citationInterleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
“It is important that inhibition of IL-10 production by T cells or malignant cells using low-dose cyclophosphamide [89], antiIL-10/IL-10R-blocking antibodies [84, 90], or anti-IL-10 antisense oligonucleotides [91] improves cancer-specific immune responses in some preclinical tumor models, which led the authors to advoc…”
BackgroundNanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Interleukin-10 production by effector T cells: Th1 cells show self control
Trinchieri, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070104 · Cited by 373
“In tumor-bearing animals, the profound anergy and unresponsiveness of tumor-infi ltrating DCs and macrophages is rapidly reversed by neutralization of IL-10 (11).”
BackgroundSelf-citationEradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
“Concentration of innate immune-stimulatory adjuvants within sentinel lymph nodes allows for the activation and maturation of dendritic cells exposed to tumor-associated antigen while preventing cytokine stormlike symptoms which occurs from systemic administration of these agents [193,194].”
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Self-citationCurrent status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C., Pereira, J. P., Bates, E. E. M., Akira, S., Vieira, P., Liu, Y.-J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7551 · Cited by 288
“Moreover, we previously showed in vivo that Ag-specific Th1 responses in the context of TLR ligation are suppressed by IL-10, and strong Th1 responses in vivo, induced by TLR ligation, are observed only when IL-10R signaling is abrogated (55, 56).”
BackgroundSelf-citationInterleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy
Sato, T., Terai, M., Tamura, Y., Alexeev, V., Mastrangelo, M. J., & Selvan, S. R. (2011) · Immunologic Research · doi:10.1007/s12026-011-8262-6 · Cited by 286
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277
Emmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 270
“The absence of IL-10 can lead to increased tumor clearance in response to intratumoral CpG injection (5), stronger T-cell immunity induced by tumor-cell vaccines (6) and it has been suggested that IL-10 contributes to the immunesuppressive environment of tumors.”
BackgroundDendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage
Perrot, I., Blanchard, D., Freymond, N., Isaac, S., Guibert, B., Pachéco, Y., & Lebecque, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2763 · Cited by 266
“Moreover, given the reported role of IL-10 in inhibiting mouse TIDC maturation in mouse tumor models (11), we analyzed whether a blocking anti-IL-10R mAb would increase the secretion of cytokines in response to TLR activation.”
BackgroundTumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 258
The tumor‐draining lymph node as an immune‐privileged site
Munn, D. H., & Mellor, A. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00444.x · Cited by 251
“CD40 ligation or treatment with CpG oligonucleotides (32, 46)].”
BackgroundMethodShirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
“(31), who reported that coadministering CpG ODN plus IL-10 receptor Ab reprogramed M2-like macrophages and DC toward an M1-like phenotype, thereby improving anti-tumor immunity.”
BackgroundPlasmacytoid dendritic cells: key players in the initiation and regulation of immune responses
Lande, R., & Gilliet, M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05152.x · Cited by 220
Dendritic cell-based immunotherapy: a basic review and recent advances
Constantino, J., Gomes, C., Falcão, A., Neves, B. M., & Cruz, M. T. (2017) · Immunologic Research · doi:10.1007/s12026-017-8931-1 · Cited by 228
“IL-10-receptor Abs demonstrated to enhance specific immune response and IL-12 production [68].”
BackgroundMetabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy
Wang, H., Franco, F., & Ho, P.-C. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.06.005 · Cited by 234
Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3185 · Cited by 222
“Tumorinfiltrating DCs have been shown to be impaired atmaturation (49).”
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19762 · Cited by 184
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Sun, Z., Fourcade, J., Pagliano, O., Chauvin, J.-M., Sander, C., Kirkwood, J. M., & Zarour, H. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3016 · Cited by 198
“The immunosuppressive role of endogenous IL10 in impeding APCs is supported by the demonstration that neutralizing IL10 with anti-IL10R antibodies is required for the stimulation of potent Th1 OVA-specific and TA-specific T-cell responses in mice treated with Toll-like receptor ligands (16, 17).”
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides
Krieg, A. M. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0019-0 · Cited by 200
“In several established mouse tumor models where CpG treatment alone had little or no activity, the combination of anti–IL-10 receptor antibody with CpG ODN induced tumor regression with a high rate of long-term survival [ 63 ].”
BackgroundInduction of potent antitumor immunity by in situ targeting of intratumoral DCs
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419762 · Cited by 180
Role of tumor-associated macrophages in the progression of hepatocellular carcinoma
Shirabe, K., Mano, Y., Muto, J., Matono, R., Motomura, T., Toshima, T., Takeishi, K., Uchiyama, H., Yoshizumi, T., Taketomi, A., et al. (2012) · Surgery Today · doi:10.1007/s00595-011-0058-8 · Cited by 174
“In one experimental study, the combination of CpG immunostimulatory oligonucleotide plus an anti-IL10 receptor antibody switched infiltrating macrophages from the M2 to the M1 phenotype and triggered an innate response that debulked large tumors [58].”
Backgroundden Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Toonen, L. W. J., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0206 · Cited by 176
“As previously shown for ex vivo–generated DC vaccines (15), both studies confirmed that maturation of in vivo–loaded DC by either agonistic anti-CD40 antibodies or the TLR9-ligand CpG-ODN was essential to induce a potent immune response.”
BackgroundKwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 175
Demoulin, S., Herfs, M., Delvenne, P., & Hubert, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812397 · Cited by 162
“[113] provided evidence that the administration of an antibody against IL-10R potentiates the efficacy of CpG ODN by reversing IL-10-induced immunosuppression.”
BackgroundSerum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
Jego, G., Bataille, R., Geffroy-Luseau, A., Descamps, G., & Pellat-Deceunynck, C. (2006) · Leukemia · doi:10.1038/sj.leu.2404226 · Cited by 164
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 176
“However, tumour-infiltrating DCs have been shown to be immature and tolerogenic and ineffective at priming T-cell responses in vivo (”
BackgroundDirecting Dendritic Cell Immunotherapy Towards Successful Cancer Treatment
Sabado, R. L., & Bhardwaj, N. (2009) · Immunotherapy · doi:10.2217/imt.09.43 · Cited by 170
The Tumor Microenvironment: A Pitch for Multiple Players
Schiavoni, G., Gabriele, L., & Mattei, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00090 · Cited by 147
“(Chaux et al., 1997a,b; Vicari et al., 2002).”
Garcia, A. J., Ruscetti, M., Arenzana, T. L., Tran, L. M., Bianci-Frias, D., Sybert, E., Priceman, S. J., Wu, L., Nelson, P. S., Smale, S. T., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00090-14 · Cited by 142
IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
Duramad, O., Fearon, K. L., Chan, J. H., Kanzler, H., Marshall, J. D., Coffman, R. L., & Barrat, F. J. (2003) · Blood · doi:10.1182/blood-2003-07-2465 · Cited by 136
Multiple facets of macrophages in renal injury
Kluth, D., Erwig, L., & Rees, A. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00773.x · Cited by 145
“TAM have a reduced ability to produce IL-12 which is a result of autocrine IL-10 production [105] and similarly dendritic cells from tumors have an immature phenotype and are refractory to stimulation with LPS and IFN-c due to IL-10 production [106].”
BackgroundDual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Siewe, L., Bollati–Fogolin, M., Wickenhauser, C., Krieg, T., Müller, W., & Roers, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200636012 · Cited by 127
Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Hargadon, K. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00192 · Cited by 141
Vicari, A. P., Luu, R., Zhang, N., Patel, S., Makinen, S. R., Hanson, D. C., Weeratna, R. D., & Krieg, A. Μ. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0586-2 · Cited by 141
“We have previously shown that neutralization of IL-10 could dramatically increase the antitumor eVect of TLR9 agonists [11, 48].”
BackgroundSelf-citationde Charette, M., & Houot, R. (2018) · Haematologica · doi:10.3324/haematol.2017.184192 · Cited by 129
Hori, Y., Winans, A. M., & Irvine, D. J. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.11.019 · Cited by 127
“CpG oligonucleotides, short single-stranded DNA oligos that mimic bacterial DNA strands and activate dendritic cells via Toll-like receptor-9, have been shown to potently activate DCs in cancer settings and to break tolerance to tumor antigens [60-64].”
Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents
Zhang, L., Zhu, G., Mei, L., Wu, C. S., Qiu, L., Cui, C., Liu, Y., Teng, I., & Tan, W. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b06987 · Cited by 124
Gut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Self-citationKortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
“Elevated Stat3 activity in tumor stromal immune cells further promotes expression of cytokines and growth factors, including but not limited to IL-10, IL-6, and VEGF, which in turn further activate Stat3 in tumor cells (9, 12, 13).”
InfluentialBerezhnoy, A., Stewart, C. A., McNamara, J. O., Thiel, W. H., Giangrande, P. H., Trinchieri, G., & Gilboa, E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.18 · Cited by 120
Self-citationBekeredjian‐Ding, I., Schäfer, M., Hartmann, E., Pries, R., Parcina, M., Schneider, P., Giese, T., Endres, S., Wollenberg, B., & Hartmann, G. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03134.x · Cited by 104
Monocytes/macrophages and/or neutrophils are the target of IL‐10 in the LPS endotoxemia model
Pils, M. C., Pisano, F., Fasnacht, N., Heinrich, J., Groebe, L., Schippers, A., Rozell, B., Jack, R. S., & Müller, W. (2010) · European Journal of Immunology · doi:10.1002/eji.200939592 · Cited by 114
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
“As a multifunctional cytotoxic molecule (102), the combination of TNF-α and its receptors (TNFR-1/TNFR-2) activates multiple signal transduction pathways, leading to diverse functions such as induction of tumor cell death by apoptosis and necrosis, stimulation of the secretion of other cytokines, and activation or rec…”
BackgroundInfluentialInterleukin‐10 in viral diseases and cancer: exiting the labyrinth?
Vicari, A. P., & Trinchieri, G. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00216.x · Cited by 123
“(106) and others with CpG plus anti-CTLA4 (143, 144).”
BackgroundSelf-citationHuman plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities
Tel, J., Smits, E. L., Anguille, S., Joshi, R. N., Figdor, C. G., & de Vries, I. J. M. (2012) · Blood · doi:10.1182/blood-2012-06-435941 · Cited by 104
Molecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 113
“reported that tumor DC function could be restored with a combination of anti-IL-10R antibodies and activation with CpG oligonucleotides [153].”
Radojcic, V., Bezak, K. B., Skarica, M., Pletneva, M. A., Yoshimura, K., Schulick, R. D., & Luznik, L. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0734-3 · Cited by 106
“Previous observations also suggested that TIDCs are functionally paralyzed due to the presence of inhibitory signals such as IL-10 and TGF- in the tumor milieu [51, 52 ].”
BackgroundResultInfluentialKuhn, S. P., Yang, J., & Ronchese, F. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00584 · Cited by 113
Tumor-induced modulation of dendritic cell function
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.008 · Cited by 127
“[53] Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, et al.”
BackgroundClinical applications of gut microbiota in cancer biology
Wong, S. H., Kwong, T. N. Y., Wu, C.-Y., & Yu, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.003 · Cited by 100
Preynat-Seauve, O., Schuler, P., Contassot, E., Beermann, F., Huard, B., & French, L. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.61 · Cited by 94
“This confirms that tumors do not irreversibly impair the ability of infiltrating DC to generate specific immune responses as previously reported (7) and opens perspectives for in vivo therapeutically oriented manipulations targeting TIDC.”
BackgroundResultInfluentialHuang, Z. D., Gan, J., Long, Z., Guo, G., Shi, X., Wang, C., Zang, Y., Ding, Z., Chen, J., Zhang, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.009 · Cited by 101
Qian, C., Jiang, X., An, H., Yu, Y., Guo, Z., Liu, S., Xu, H., & Cao, X. (2006) · Blood · doi:10.1182/blood-2006-03-005595 · Cited by 96
Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells
Stoitzner, P., Green, L. K., Jung, J. Y., Price, K. M., Atarea, H., Kivell, B. M., & Ronchese, F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0487-4 · Cited by 96
“F0 melanoma demonstrated that part of the TIDC isolated displayed a mature phenotype [26].”
BackgroundLu, H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00083 · Cited by 95
“The addition of antiIL-10R to TLR9 agonist CpG also exhibited robust anti-tumor activity exceeding by far that of CpG alone, and elicited antitumor immune memory (10).”
BackgroundAnderson, M. J., Shafer-Weaver, K., Greenberg, N. M., & Hurwitz, A. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1268 · Cited by 91
“Various stimuli, such as pathogen byproducts that stimulate TLRs (6, 7), activated CD4 T cells (8), and even CD8 T cells (9) can provide the appropriate signals to activate tolerogenic DCs.”
BackgroundThe role of microbiota in cancer therapy
Perez-Chanona, E., & Trinchieri, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.003 · Cited by 90
Self-citationMcDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R. A., Currie, A. J., & Robinson, B. W. S. (2015) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 86
From cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 107
“(148) reported that defective tumorinfiltrating DCs could be rescued into efficient APCs by the combined administration of CpG ODN and anti-IL-10R mAb but not by each agent on their own.”
BackgroundTLR9 Signaling in the Tumor Microenvironment Initiates Cancer Recurrence after Radiotherapy
Gao, C., Kozłowska, A. K., Nechaev, S., Li, H., Zhang, Q., Hossain, D. M. S., Kowolik, C. M., Chu, P. G., Swiderski, P. M., Diamond, D. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1314 · Cited by 95
“Previous studies revealed that STAT3 is a negative feedback inhibitor for proinflammatory signaling by TLR4 and TLR9 in myeloid cells (22, 23).”
Ito, S.-E. A., Shirota, H., Kasahara, Y., Saijo, K., & Ishioka, C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2043-6 · Cited by 92
Bourquin, C., Hotz, C., Noerenberg, D., Voelkl, A., Heidegger, S. M., Roetzer, L. C., Storch, B., Sandholzer, N., Wurzenberger, C., Anz, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3903 · Cited by 86
“Prestimulation with R848 leads to increased IL-10 secretion upon secondary stimulation The induction of the anti-inflammatory cytokine IL-10 has been shown to decrease immune responses upon treatment with TLR7 and TLR9 agonists (20, 21).”
Background
Metadata
- Authors
- Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
- Affiliations
- 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Inserm (FR)
- 4DNAX Research Institute, Palo Alto, CA 94304
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-19
- Volume
- 196
- Issue
- 4
- Pages
- 541-549
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2196048
- OpenAlex
- W2156592930
- Cited by
- 343
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.